Traws Pharma (TRAW) Proxy filing summary

Executive summary

• Special meeting scheduled for Dec. 3, 2026, at 9:00 a.m. ET by live webcast; shareholders will vote on reverse-split authority and possible adjournment to solicit votes.

• Reverse split is intended chiefly to regain Nasdaq’s $1.00 minimum bid-price compliance; notice set Jan. 25, 2027 as the initial compliance deadline, with delisting risk if approval is denied.

Voting matters and shareholder proposals

• Proposal 1 seeks authority for a 1-for-8 to 1-for-15 reverse split, with the Board selecting the ratio and acting within 12 months of approval, without another shareholder vote.

• Proposal 2 would allow adjournment to solicit additional proxies if votes are insufficient; both proposals require a majority of votes cast for or against, and abstentions have no effect.

• The Board recommends voting For both proposals; record date is Oct. 6, 2026, with one vote per outstanding common share.

Board of directors and corporate governance

• The Board unanimously approved the reverse-split proposal on Oct. 6, 2026, and may set the ratio, implement the split, or abandon it before filing the amendment.

• Board factors include marketability and liquidity, prevailing market conditions, Nasdaq requirements, expected share-price effects, and capitalization.